Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
9.05
0.00
(0.00%)
At close: 5:00:01 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
0.10
--
0.40
122,936.40
Cost of Revenue
782.89
1,645.68
1,634.57
2,773.49
38,405.19
Gross Profit
-782.89
-1,645.58
-1,634.57
-2,773.09
84,531.21
Operating Expense
21,037.97
20,458.14
15,352.84
10,991.21
10,827.02
Operating Income
-21,820.86
-22,103.71
-16,987.40
-13,764.30
73,704.20
Net Non Operating Interest Income Expense
1,685.21
4,348.58
1,792.95
-6.47
117.78
Pretax Income
-20,688.72
-18,308.20
-15,263.70
-13,636.32
73,654.13
Tax Provision
--
--
--
--
5,691.50
Net Income Common Stockholders
-20,688.72
-18,308.20
-15,263.70
-13,636.32
67,962.63
Diluted NI Available to Com Stockholders
-20,688.72
-18,308.20
-15,263.70
-13,636.32
67,962.63
Basic EPS
-1.23
-1.09
-1.09
-0.98
5.00
Diluted EPS
-1.23
-1.09
-1.09
-0.98
4.90
Basic Average Shares
16,836
16,836
14,030
13,951.57
13,600
Diluted Average Shares
16,836
16,836
14,030
13,955.90
13,860.64
Total Operating Income as Reported
-21,820.86
-22,103.71
-16,987.40
-13,764.30
73,704.20
Total Expenses
21,820.86
22,103.81
16,987.40
13,764.70
49,232.21
Net Income from Continuing & Discontinued Operation
-20,688.72
-18,308.20
-15,263.70
-13,636.32
67,962.63
Normalized Income
-20,688.72
-18,308.20
-15,263.70
-13,636.32
67,962.63
Interest Income
1,683.87
4,391.62
1,911.22
0
140.74
Interest Expense
46.48
46.41
16.36
6.24
21.52
Net Interest Income
1,685.21
4,348.58
1,792.95
-6.47
117.78
EBIT
-20,642.24
-18,261.79
-15,247.34
-13,630.08
73,675.65
EBITDA
-18,032
-16,413.90
-13,934.19
-13,330.27
73,894.02
Reconciled Cost of Revenue
782.89
1,645.68
1,634.57
2,773.49
38,405.19
Reconciled Depreciation
2,610.24
1,847.89
1,313.16
299.82
218.37
Net Income from Continuing Operation Net Minority Interest
-20,688.72
-18,308.20
-15,263.70
-13,636.32
67,962.63
Normalized EBITDA
-18,032
-16,413.90
-13,934.19
-13,330.27
73,894.02
Tax Rate for Calcs
--
--
--
--
0
12/31/2020 - 4/19/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
96X.F FluoGuide A/S
3.7650
+0.27%
RGO.DU Regeneron Pharmaceuticals Inc
658.20
+0.12%
PH4.F CStone Pharmaceuticals
0.3720
0.00%
MAGLE.ST Magle Chemoswed Holding AB (publ)
32.60
-3.55%
600161.SS TIANTAN BIO
19.93
-0.60%
HQ1.MU Oruka Therapeutics Inc. R
10.60
0.00%
BSSP Baseline Productions, Inc.
0.0001
0.00%
GYX.F Futura Medical plc
0.1330
-24.86%
BXPHF Botanix Pharmaceuticals Limited
0.2650
-8.62%
10VA.F Immunic, Inc.
1.1250
-8.98%